These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus. Geraminejad P; Stone MS; Sontheimer RD Lupus; 2004; 13(6):473-7. PubMed ID: 15303576 [TBL] [Abstract][Full Text] [Related]
7. Capecitabine-induced Subacute Cutaneous Lupus Erythematosus. Rocha A; Almeida HL; Zerwes G; Oliveira Filho UL An Bras Dermatol; 2019; 94(5):618-619. PubMed ID: 31777367 [No Abstract] [Full Text] [Related]
8. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M; J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097 [TBL] [Abstract][Full Text] [Related]
9. Drug-induced subacute cutaneous lupus erythematosus related to doxycycline. Miller KK; Chu J; Patel R; Kamino H Dermatol Online J; 2011 Oct; 17(10):3. PubMed ID: 22031629 [TBL] [Abstract][Full Text] [Related]
10. Subacute cutaneous lupus erythematosus starting as linear lupus erythematosus. Frances L; Betlloch I; Leiva-Salinas M; Marin I; Pascual JC Int J Dermatol; 2016 Feb; 55(2):173-6. PubMed ID: 26235783 [TBL] [Abstract][Full Text] [Related]
11. A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature. Yildirim Cetin G; Sayar H; Ozkan F; Kurtulus S; Kesici F; Sayarlioglu M Lupus; 2013 Jul; 22(8):839-46. PubMed ID: 23761100 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826 [TBL] [Abstract][Full Text] [Related]
13. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study. Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. Adachi A; Horikawa T J Dermatol; 2007 Jul; 34(7):473-6. PubMed ID: 17584326 [TBL] [Abstract][Full Text] [Related]
15. [A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel]. Suzuki M Gan To Kagaku Ryoho; 2007 Jan; 34(1):69-72. PubMed ID: 17220673 [TBL] [Abstract][Full Text] [Related]
16. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613 [TBL] [Abstract][Full Text] [Related]
17. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus in a patient with progressive systemic sclerosis. Aiempanakit K; Chiratikarnwong K; Juthong S; Auepemkiate S Lupus; 2018 Oct; 27(11):1860-1863. PubMed ID: 30028256 [TBL] [Abstract][Full Text] [Related]
18. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999 [TBL] [Abstract][Full Text] [Related]
19. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]. Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072 [TBL] [Abstract][Full Text] [Related]
20. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]